DAC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-31. Anything still debated is marked as such rather than presented as settled.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
=== Depression === Several studies have shown that antidepressant drugs that have combined serotonergic and noradrenergic activity are generally more effective than SSRIs, which act upon serotonin reuptake by themselves. Serotonergic-noradrenergic antidepressant drugs may have a modest efficacy advantage compared to SSRIs in treating major depressive disorder (MDD), but are slightly less well tolerated. Further research is needed to examine the possible differences in efficacy in specific MDD sub-populations or for specific MDD symptoms, between these classes of antidepressant drugs.
== Discovery and production == During the 1950s and 1960s, the National Cancer Institute carried out a wide-ranging program of screening plant and marine organism material. As part of that program, extract from the sea squirt Ecteinascidia turbinata was found to have anticancer activity in 1969. Separation and characterization of the active molecules had to wait many years for the development of sufficiently sensitive techniques, and the structure of one of them, Ecteinascidin 743, was determined by KL Rinehart at the University of Illinois in 1984. Rinehart had collected his sea squirts by scuba diving in the reefs of the West Indies. The biosynthetic pathway responsible for producing the drug has been determined to come from Candidatus Endoecteinascidia frumentensis, a microbial symbiont of the tunicate. The Spanish company PharmaMar licensed the compound from the University of Illinois before 1994 and attempted to farm the sea squirt with limited success. Yields from the sea squirt are extremely low as around 1,000 kilograms of animals is needed to isolate 1 gram of trabectedin - and about 5 grams were believed to be needed for a clinical trial so Rinehart asked the Harvard chemist E. J. Corey to search for a synthetic method of preparation. His group developed such a method and published it in 1996. This was later followed by a simpler and more tractable method which was patented by Harvard and subsequently licensed to PharmaMar.
As of 2025, the artificial intelligence (AI) market in the United Kingdom is worth over £21 billion, and is expected to exceed £1 trillion by 2035. It is the world's third-largest AI market and consistently ranked 3rd in private AI funding between 2013 and 2024, both behind the United States and China. The country ranked fifth globally in a 2024 report on AI development by Stanford University. In the first (2024) edition of GIRAI, the United Kingdom was ranked 4th out of 138 countries assessed and in the second (2026) edition, the country rank fell to 7th out of 135 countries. The UK AI market is valued at over £21 billion in 2025 and projected to exceed £1 trillion by 2035. The UK's prominence is rooted in a strong historical foundation, beginning with Alan Turing's theoretical work in the 1930s and 1940s, and the establishment of early AI research centres in the 1960s, such as those at the University of Edinburgh. Despite periods of reduced funding known as "AI winters", modern UK AI research has seen significant breakthroughs, most notably through London-based DeepMind's achievements in deep reinforcement learning and protein structure prediction. The UK AI sector has experienced rapid growth. The number of AI companies increased by 85% between 2022 and 2024, reaching 5,862 firms. In 2024, the sector generated an estimated £23.9 billion in revenue and £11.8 billion in Gross Value Added (GVA), employing over 86,000 people.
So far, no known necrotoxins have been isolated from the venom of any of these spiders, and some arachnologists have disputed the accuracy of spider identifications carried out by bite victims, family members, medical responders, and other non-experts in arachnology. There have been several studies questioning the danger posed by some of the other spiders mentioned: In these studies, scientists examined case studies of bites in which the spider in question was identified by an expert, and found that the incidence of necrotic injury diminished significantly when "questionable" identifications were excluded from the sample set.
Sources: en.wikipedia.org
On November 27, The Washington Post published an article alleging that Secretary of Defense Pete Hegseth had ordered the officers responsible for the first airstrike on September 2, 2025, to "kill everyone" on board, prompting Admiral Frank M. Bradley to order a second strike to kill the two survivors of the initial strike, who were clinging to the wreckage of the boat that had been by the initial strike. As no quarter orders are forbidden under the Law of war, the second September 2 strike was widely criticized as constituting a war crime even under the Trump Administration's justification for the boat strike campaign in general, with the chair of the United States Senate Committee on Armed Services, Republican Senator Roger Wicker, along with ranking member Jack Reed, promising "vigorous oversight to determine the facts related to these circumstances". According to The New York Times, five U.S. officials stated that while Hegseth did, on September 2, order the killing of all individuals aboard the alleged drug boat, he did not specifically address what was to be done if any individuals survived the initial strike and was not present when Bradley carried out the second strike. After Hegseth refused to release a video of the second strike to Congress, the United States Senate placed a provision in the 2026 National Defense Authorization Act holding back a quarter of Hegseth's travel budget until he showed the video to lawmakers.
==== Overview ==== In July 2012, GSK pleaded guilty in the United States to criminal charges, and agreed to pay US$3 billion, in what was the largest settlement until then between the Justice Department and a drug company. The US$3 billion included a criminal fine of US$956,814,400 and forfeiture of US$43,185,600. The remaining US$2 billion covered a civil settlement with the government under the False Claims Act. The investigation was launched largely on the basis of information from four whistleblowers who filed qui tam (whistleblower) lawsuits against the company under the False Claims Act. The charges stemmed from GSK's promotion of the anti-depressants Paxil (paroxetine) and Wellbutrin (bupropion) for unapproved uses from 1998 to 2003, specifically as suitable for patients under the age of 18, and from its failure to report safety data about Avandia (rosiglitazone), both in violation of the Federal Food, Drug, and Cosmetic Act. Other drugs promoted for unapproved uses were two inhalers, Advair (fluticasone/salmeterol) and Flovent (fluticasone propionate), as well as Zofran (ondansetron), Imitrex (sumatriptan), Lotronex (alosetron) and Valtrex (valaciclovir). The settlement also covered reporting false best prices and underpaying rebates owed under the Medicaid Drug Rebate Program, and kickbacks to physicians to prescribe GSK's drugs. There were all-expenses-paid spa treatments and hunting trips for doctors and their spouses, speakers' fees at conferences, and payment for articles ghostwritten by the company and placed by physicians in medical journals.
=== Termination === Macrolides and clindamycin (both also having other potential mechanisms) cause premature dissociation of the peptidyl-tRNA from the ribosome. Puromycin has a structure similar to that of the tyrosinyl aminoacyl-tRNA. Thus, it binds to the ribosomal A site and participates in peptide bond formation, producing peptidyl-puromycin. However, it does not engage in translocation and quickly dissociates from the ribosome, causing a premature termination of polypeptide synthesis. Streptogramins also cause premature release of the peptide chain.
== Regulation == Transcriptional regulation of MMP-13 is tightly controlled due to its potent proteolytic capacity. There are several binding domains for various transcription factors including AP-1, PEA-3 and OSE-2 as well as a sequence with homology to a TGF-β inhibitory element (TIE). Moreover, several cytokines and growth factors have been demonstrated to affect Mmp13 gene expression, including parathyroid hormone, IGF-1, TGF-β, hepatocyte growth factor and many inflammatory cytokines such as IL-1α and IL-1β. The upstream regulatory region of the Mmp13 gene contains a number of transcription factor binding sites but it was recently discovered that there is a conserved forkhead response element (FHRE) consensus sequence for FOXO3a in the human, mouse and rat Mmp13 promoter. Endogenous FOXO3a activation results in marked upregulation of Mmp13 expression which is capable of promoting extracellular matrix degradation and apoptotic cell death.
There has been uncertainty about which biological target interactions mediate the psychoactive and other effects of ibogaine. Rodent drug discrimination studies with ibogaine have been employed to help elucidate these interactions. Ibogaine partially substitutes for the serotonergic psychedelics LSD and DOM and this can be blocked by the serotonin 5-HT2 receptor antagonist pizotifen. Similarly, LSD and DOM partially substitute for ibogaine and this can be blocked by the serotonin 5-HT2A receptor antagonist pirenperone. The serotonin releasing agent and potent serotonin 5-HT2 receptor agonist fenfluramine also partially substitutes for ibogaine. The preferential serotonin 5-HT2C receptor agonists MK-212 and mCPP partially substitute for ibogaine as well and this can be blocked by the serotonin 5-HT2 receptor antagonist metergoline. The preceding findings suggest that serotonin 5-HT2A and 5-HT2C receptor activation are involved in the subjective effects of ibogaine. Conversely, the serotonin 5-HT1A and 5-HT3 receptors do not appear to be involved. Although serotonin 5-HT2A receptor signaling appears to be involved in the effects of ibogaine, neither ibogaine nor its major active metabolite noribogaine appears to act as a direct serotonin 5-HT2A receptor agonist. In addition, in contrast to the findings in drug discrimination studies, ibogaine fails to produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.
Sources: en.wikipedia.org
Senate majority leader John Thune set a goal of passing the Senate's version of OBBBA by July 4, 2025. On June 20, 2025, the Senate parliamentarian, Elizabeth MacDonough, ruled that several provisions from the Senate committees on Banking, Environment and Public Works, and Armed Services violated the Byrd Rule and could not be included in a 50-vote reconciliation bill. The bill will no longer be able to include a funding cap on the Consumer Financial Protection Bureau, $1.4 billion in pay cuts to Federal Reserve staff, a $293 million cut in funding for the Office of Financial Research, the elimination of the Public Company Accounting Oversight Board, a repeal of portions of the Inflation Reduction Act, a repeal of the Environmental Protection Agency's "multipollutant emissions standards" for certain vehicles built after the 2026 model year, and a provision to cut funding for the Department of Defense if spending requests are not made on time. By June 24, the parliamentarian also ruled against a provision that would make it harder for a plaintiff to sue in order to impose injunctions or restraining orders against the federal government, a provision allowing states to conduct enforcement at the United States border, a provision forcing the United States Postal Service to sell electric vehicles, the REINS Act, a provision to allow developers to bypass environmental review by paying a fee, and a provision forcing states to pay at least 5% of SNAP costs.
There are concerns that some users may find it hard to stop using TikTok. Internal TikTok research has documented the addiction potential of the app. In April 2018, an addiction-reduction feature was added to Douyin. This encouraged users to take a break every 90 minutes. Later in 2018, the feature was rolled out to the TikTok app. TikTok uses popular influencers to encourage viewers to stop using the app and take a break. Many were also concerned with the app affecting users' attention spans due to the short-form nature of the content. This is a concern as many of TikTok's audience are younger children, whose brains are still developing. TikTok executives and representatives have noted and made aware to advertisers on the platform that users have poor attention spans. The company's survey reported that nearly 50% of social media users find it stressful to watch a video longer than a minute and a third of users watch videos at double speed. Their short attention spans posed a challenge for TikTok to pivot towards longer content formats. TikTok has also received criticism for enabling children to purchase coins which they can send to other users. Daily hours of entertainment screen media (Social Medias) may displace healthy behaviors such as socializing face to face, chores, hobbies, homework, family meals time, exercise, and sufficient sleep. Insomnia is considered a strong mediator between screen media time and mental health symptoms which implies that engaging in screen time pushes out adequate sleep and leads to decreased mental health.
=== Inherited Neurodegenerative Diseases === In 2022, a new autosomal-recessive disease was discovered that is caused by mutations of the CTR1 gene. The disease is characterized by profound deficiency of copper in the central nervous system and presents with infantile seizures and neurodegeneration. hCTR1 has been implicated in neurological disorders. Copper imbalance is a hallmark of various neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, where amyloid-β peptides bind copper and generate oxidative stress. Furthermore is's associated with Huntington’s disease, prion diseases, and Amyotrophic lateral sclerosis. The hCTR1-Atox1-ATP7A/B axis is also associated with Menkes disease and Wilson’s disease, in both cases the pathology is driven primarily by mutations in proteins that regulate copper homeostasis, most notably disease-causing mutations in ATP7A or ATP7B, which lead to systemic copper deficiency or copper overload. Moreover, the human eye, and particularly the retina, is composed of highly specialized neurons, and hCTR1 plays a vital role in maintaining copper homeostasis across ocular tissues. Increased hCTR1 expression has been reported in patients with Eales disease and copper has been identified as a major driver of vision loss in ischemic and diabetic retinopathies.
In a systematic review of published evidence, the United States Preventive Services Task Force in 2017 concluded that there was uncertainty about the accuracy or clinical utility of all potential screening tools for OSA, and recommended that evidence is insufficient to assess the balance of benefits and harms of screening for OSA in asymptomatic adults. The diagnosis of OSA syndrome is made when the patient shows recurrent episodes of partial or complete collapse of the upper airway during sleep resulting in apneas or hypopneas, respectively. Criteria defining an apnea or a hypopnea vary. The American Academy of Sleep Medicine (AASM) defines apnea as a reduction in airflow of ≥ 90% lasting at least 10 seconds. A hypopnea is defined as a reduction in airflow of ≥ 30% lasting at least 10 seconds and associated with a ≥ 4% decrease in pulse oxygenation, or as a ≥ 30% reduction in airflow lasting at least 10 seconds and associated either with a ≥ 3% decrease in pulse oxygenation or with an arousal. To define the severity of the condition, the Apnea-Hypopnea Index (AHI) or the Respiratory Disturbance Index (RDI) are used. While the AHI measures the mean number of apneas and hypopneas per hour of sleep, the RDI adds to this measure the respiratory effort-related arousals (RERAs). The OSA syndrome is thus diagnosed if the AHI is > 5 episodes per hour and results in daytime sleepiness and fatigue or when the RDI is ≥ 15 independently of the symptoms.
Stratum corneum Stratum lucidum (only in palms and soles) Stratum granulosum Stratum spinosum Stratum basale (also called the stratum germinativum) Keratinocytes in the stratum basale proliferate through mitosis and the daughter cells move up the strata changing shape and composition as they undergo multiple stages of cell differentiation to eventually become anucleated. During that process, keratinocytes will become highly organized, forming cellular junctions (desmosomes) between each other and secreting keratin proteins and lipids which contribute to the formation of an extracellular matrix and provide mechanical strength to the skin. Keratinocytes from the stratum corneum are eventually shed from the surface (desquamation). The epidermis contains no blood vessels, and cells in the deepest layers are nourished by diffusion from blood capillaries extending to the upper layers of the dermis.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.